查看文章

Fig. 1| Changes in the cancer cell therapy pipeline by therapy type and year. Comparison of cell therapy agent development pipeline across various therapy types from 2020 to 2022. APC, antigenpresenting cell; CIK, cytokine-induced killer; NK, natural killer; RBC, red blood cell; TAA, tumourassociated antigen; TCR, Tácell receptor; TIL, tumour-infiltrating lymphocyte; TSA, tumour-specific antigen. The pie chart shows the composition of the ‘other cell therapies’ category in 2022.